Ultomiris Resources Here you can find resources to download and access related to ULTOMIRIS® (ravulizumab) as a treatment of adult and paediatric patients with a body weight of 10 kg or above with PNH.1

Please click the links below to be redirected to a third-party website, where you can access and find more information on these selected publications.


Alexion is not the copyright holder of either the journal or the articles – such copyright(s) is/are held by the publisher(s) and/or the author(s) of the journal and/or article as appropriate. Alexion has provided the weblinks to the full article(s) merely to assist the reader and on the basis that the relevant article(s) is/are either available as ‘open access’ or via a subscription service which the reader may already subscribe to. Alexion assumes no responsibility for ascertaining if the reader has appropriate copyright licence for use of the relevant article and Alexion makes no attempt to provide any licence or permission to the reader – all such permissions and ownership rest exclusively with their owners.
Please report any adverse events via your national reporting system. Adverse events can also be reported to Alexion, AstraZeneca Rare Disease by contacting: https://contactazmedical.astrazeneca.com/
PNH; Paroxysmal nocturnal hemoglobinuria                                                                                                                                                                                                                               
ULTOMIRIS® EU Summary of Product Characteristics available at https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf. Last accessed January 2026. Lee JW, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133:530–539. Kulasekararaj AG, et al. Ravulizumab (ALXN1210) vs eculizumab in C5‑inhibitor–experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540–549. Schrezenmeier H, et al. One‑year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naive to complement inhibitor therapy: open‑label extension of a randomized study. Therapeutics of Advanced Hematology. 2020;11:2040620720966137. Kulasekararaj AG, et al. One‑year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab. European Journal of Haematology 2021. Kulasekararaj AG, et al. Long‑term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‑year results from two pivotal phase 3 studies. European Journal of Haematology 2022. Kulasekararaj AG, et al. Ravulizumab demonstrates long‑term (up to 6 years) efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria. Annals of Hematology 2025. Schrezenmeier H, et al. Predictors for improvement in patient‑reported outcomes: post hoc analysis of a phase 3 randomized, open‑label study of eculizumab and ravulizumab in complement inhibitor‑naive patients with paroxysmal nocturnal hemoglobinuria. Annals of Hematology. 2024. Chonat C, et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria. Blood Advances. 2024;8(11):2813–2824.